1. Scrip
  2. >>COVID-19

World A Step Closer To First Human Plasmid DNA Vaccine As Zydus Seeks EUA

COVID-19 Candidate Effective Against Delta Variant

 
• By Vibha Ravi

A plasmid DNA vaccine for human use has moved a step closer to reality, with Zydus Cadila applying for an accelerated nod for its COVID-19 candidate in India. 67% efficacy reported in an interim data readout and Delta variant being the prominent strain during a Phase III trial imply better odds for approval.

DNA strand
Plasmid DNA Vaccine For Humans Close To Finish Line • Source: Alamy

Zydus Cadila’s application to the Indian regulator for an accelerated nod or emergency use authorization (EUA) for its COVID-19 vaccine takes the world a step closer to the first plasmid DNA vaccine approved for human use.

While vaccines made with recombinant DNA technology, like Recombivax and Engerix-B for hepatitis B, have been approved by the US Food and Drug Administration (FDA) and veterinary DNA vaccines are in use, the contender

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

Stock Watch: Q3, Bonfire Of The Vaccine Manufacturers

 
• By Andy Smith

Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.

Meiji Considers Legal Action Amid Japan Misinformation On Kostaive Vaccine

 
• By Lisa Takagi

Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.

More from Scrip

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.